Scarica l'app Stockscreener
17.00
0.10%
0.0175
Dopo l'orario di chiusura:
16.55
-0.45
-2.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.98
Aprire:
$16.95
Volume 24 ore:
14,229
Relative Volume:
0.57
Capitalizzazione di mercato:
$22.54M
Reddito:
$40.93M
Utile/perdita netta:
$-23.82M
Rapporto P/E:
-45.95
EPS:
-0.37
Flusso di cassa netto:
$-37.87M
1 W Prestazione:
+0.00%
1M Prestazione:
+4.55%
6M Prestazione:
+53.43%
1 anno Prestazione:
-18.46%
Intervallo 1D:
$16.88
$17.25
Intervallo di 1 settimana:
$16.51
$17.47
Portata 52W:
$6.20
$23.20
Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile
Nome
Pieris Pharmaceuticals Inc
Settore
Industria
Telefono
857-246-8998
Indirizzo
225 FRANKLIN STREET, BOSTON, MA
Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Pieris Pharmaceuticals Inc Borsa (PIRS) Ultime notizie
Pieris Pharmaceuticals: Q2 Earnings Snapshot - Barchart
Pieris Pharmaceuticals director buys series F preferred stock for $1 By Investing.com - Investing.com South Africa
Pieris Pharmaceuticals director buys series F preferred stock for $1 - Investing.com
(PIRS) Technical Data - Stock Traders Daily
pieris pharmaceuticals, inc. Earnings dates - RTTNews
Learn to Evaluate (PIRS) using the Charts - Stock Traders Daily
(PIRS) Trading Signals - Stock Traders Daily
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Sees Significant Decrease in Short Interest - Defense World
How the (PIRS) price action is used to our Advantage - Stock Traders Daily
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
(PIRS) Investment Analysis and Advice - Stock Traders Daily
Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World
Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com
(PIRS) Long Term Investment Analysis - Stock Traders Daily
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World
Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News
Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve
General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Business Wire
Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal
Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga
PIRS Stock on the Rise: A Promising Investment - The InvestChronicle
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace
Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble
Palvella and Pieris to merge - The Pharma Letter
Pieris Pharma stock surges on merger deal (NASDAQ:PIRS) - Seeking Alpha
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Crosses Below 50 Day Moving Average of $9.25 - Defense World
Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics - MarketWatch
Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading - Stocks Telegraph
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Yahoo Finance
Troutman Pepper Advises Palvella Therapeutics in Merger with Pieris Pharmaceuticals - Troutman Pepper
MEIP Stock sees a Significant Surge Amidst Strategic Evaluation - BP Journal
(PIRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - American Banking and Market News
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30% - Simply Wall St
(PIRS) Technical Pivots with Risk Controls - Stock Traders Daily
Pieris loses Servier as partner for cancer immunotherapies - pharmaphorum
Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pieris Pharmaceuticals Inc Azioni (PIRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pieris Pharmaceuticals Inc Azioni (PIRS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 12 '24 |
Buy |
15.88 |
3,000 |
47,647 |
129,574 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 09 '24 |
Buy |
14.89 |
3,000 |
44,679 |
127,331 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):